Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2017 Apr 5

PMID 28376175

Citations 135

Authors

Karoline B Kuchenbaecker

Lesley McGuffog

Daniel Barrowdale

Andrew Lee

Penny Soucy

Joe Dennis

Susan M Domchek

Mark Robson

Amanda B Spurdle

Susan J Ramus

Nasim Mavaddat

Mary Beth Terry

Susan L Neuhausen

Rita Katharina Schmutzler

Jacques Simard

Paul D P Pharoah

Kenneth Offit

Fergus J Couch

Georgia Chenevix-Trench

Douglas F Easton

Antonis C Antoniou

Affiliations

Soon will be listed here.

Abstract

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates.

Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS.

Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2×10 -53 ). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2×10 -20 ). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS.

Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management.

Citing Articles

Risk of Cervical Carcinoma After Unfavorable Behavior and High Genetic Risk in the UK Biobank: A Prospective Nested Case-Control Study.

Liu S, Guan Y, Lin S, Wu P, Zhang Q, Chu T Biomedicines. 2025; 13(2).

PMID: 40002877 PMC: 11853234. DOI: 10.3390/biomedicines13020464.

Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.

Manna E, Serrano D, Cazzaniga L, Mannucci S, Zanzottera C, Fava F Genes (Basel). 2025; 16(1).

PMID: 39858629 PMC: 11764557. DOI: 10.3390/genes16010082.

Evaluation of Multiple Breast Cancer Polygenic Risk Score Panels in Women of Latin American Heritage.

Huang X, Lott P, Hu D, Zavala V, Jamal Z, Vidaurre T Cancer Epidemiol Biomarkers Prev. 2024; 34(2):234-245.

PMID: 39625644 PMC: 11799839. DOI: 10.1158/1055-9965.EPI-24-1247.

Implementation of risk assessment process for breast cancer risk in primary care.

Marrison S, Allen C, Hughes K, Raines H, Banks M, Lee T J Cancer Prev Curr Res. 2024; 15(3):65-69.

PMID: 39346015 PMC: 11434167. DOI: 10.15406/jcpcr.2024.15.00552.

HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles.

Kuligina E, Romanko A, Jankevic T, Martianov A, Ivantsov A, Sokolova T Breast Cancer Res Treat. 2024; 209(2):341-354.

PMID: 39306605 DOI: 10.1007/s10549-024-07497-2.

References

Lin W, Camp N, Ghoussaini M, Beesley J, Michailidou K, Hopper J . Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Hum Mol Genet. 2014; 24(1):285-98. PMC: 4334820. DOI: 10.1093/hmg/ddu431. View

Mavaddat N, Pharoah P, Michailidou K, Tyrer J, Brook M, Bolla M . Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015; 107(5). PMC: 4754625. DOI: 10.1093/jnci/djv036. View

Rivera C, Grossardt B, Rhodes D, Brown Jr R, Roger V, Melton 3rd L . Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2008; 16(1):15-23. PMC: 2755630. DOI: 10.1097/gme.0b013e31818888f7. View

Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E . Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013; 105(11):812-22. DOI: 10.1093/jnci/djt095. View

Antoniou A, Beesley J, McGuffog L, Sinilnikova O, Healey S, Neuhausen S . Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010; 70(23):9742-54. PMC: 2999830. DOI: 10.1158/0008-5472.CAN-10-1907. View

Gaudet M, Kuchenbaecker K, Vijai J, Klein R, Kirchhoff T, McGuffog L . Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet. 2013; 9(3):e1003173. PMC: 3609647. DOI: 10.1371/journal.pgen.1003173. View

Aulchenko Y, Ripke S, Isaacs A, Van Duijn C . GenABEL: an R library for genome-wide association analysis. Bioinformatics. 2007; 23(10):1294-6. DOI: 10.1093/bioinformatics/btm108. View

Antoniou A, Goldgar D, Andrieu N, Chang-Claude J, Brohet R, Rookus M . A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet Epidemiol. 2005; 29(1):1-11. DOI: 10.1002/gepi.20074. View

Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N . Incorporating genomics into breast and prostate cancer screening: assessing the implications. Genet Med. 2013; 15(6):423-32. PMC: 3941015. DOI: 10.1038/gim.2012.167. View

10.

Couch F, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker K . Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212. PMC: 3609646. DOI: 10.1371/journal.pgen.1003212. View

11.

Harrell Jr F, Califf R, Pryor D, Lee K, Rosati R . Evaluating the yield of medical tests. JAMA. 1982; 247(18):2543-6. View

12.

Ghoussaini M, Edwards S, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K . Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun. 2014; 4:4999. PMC: 4321900. DOI: 10.1038/ncomms5999. View

13.

Southey M, Goldgar D, Winqvist R, Pylkas K, Couch F, Tischkowitz M . PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016; 53(12):800-811. PMC: 5200636. DOI: 10.1136/jmedgenet-2016-103839. View

14.

Anderson K, Jacobson J, Heitjan D, Graff Zivin J, Hershman D, Neugut A . Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006; 144(6):397-406. DOI: 10.7326/0003-4819-144-6-200603210-00006. View

15.

Dunning A, Michailidou K, Kuchenbaecker K, Thompson D, French J, Beesley J . Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016; 48(4):374-86. PMC: 4938803. DOI: 10.1038/ng.3521. View

16.

Rocca W, Grossardt B, de Andrade M, Malkasian G, Melton 3rd L . Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006; 7(10):821-8. DOI: 10.1016/S1470-2045(06)70869-5. View

17.

Tung N, Domchek S, Stadler Z, Nathanson K, Couch F, Garber J . Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016; 13(9):581-8. PMC: 5513673. DOI: 10.1038/nrclinonc.2016.90. View

18.

Rivera C, Grossardt B, Rhodes D, Rocca W . Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology. 2009; 33(1):32-40. PMC: 2697609. DOI: 10.1159/000211951. View

19.

Evans D, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam A . Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev. 2009; 18(8):2318-24. DOI: 10.1158/1055-9965.EPI-09-0171. View

20.

Bojesen S, Pooley K, Johnatty S, Beesley J, Michailidou K, Tyrer J . Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013; 45(4):371-84, 384e1-2. PMC: 3670748. DOI: 10.1038/ng.2566. View